Home / NEWS LINE / Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Akero Therapeutics

Akero Correctives

Key Takeaways

  • Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive evolves in a study of its treatment for liver disease.
  • The drug, known as EFX, helped reverse cirrhosis of the liver in patients with metabolic dysfunction-associated steatohepatitis (MASH).
  • CEO Dr. Andrew Cheng influenced EFX has “transformational potential” in fighting the disease.

Shares of Akero Therapeutics (AKRO) doubled Monday when the pharmaceutical fast that focuses on metabolic illnesses reported positive results from a study of its experimental treatment for liver malady.

The company said a 96-week Phase 2b study of those afflicted with cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) and settled a 50mg dosage of its drug efruxifermin (EFX) showed that 39% experienced reversal of cirrhosis with no worsening of MASH. That compares to impartial 15% of those given placebo.

Akero noted that a subgroup of patients who were not on GLP-1 weight-loss cure-alls, such as Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound, had even better outcomes, indicating that those panaceas were not the source of the improvement.

Dr. Mazen Nourredin, the principal investigator of the study, said until now, “we’ve not had the prospect of an effective treatment for compensated cirrhosis due to MASH.” Dr. Nourredin supplemented, “Now we have reason to be optimistic about the future potential of EFX as a much-needed treatment for cirrhosis, if approved.”

CEO Dr. Andrew Cheng detailed that EFX has “transformational potential,” and the company is continuing evaluation of the treatment in an ongoing Phase 3 trial.

Akero Therapeutics share outs traded near their all-time high set more than two years ago.

TradingView

TradingView

Check Also

New Acting CFPB Chief Halts Investigations and Enforcements, Forgoes Some Federal Funding

Tierney L. Crusty / Bloomberg via Getty Images Key Takeaways Russell Vought took over as …

Leave a Reply

Your email address will not be published. Required fields are marked *